This approach resulted in novel treatment options which in particular improve the life of young children. (sciforum.hu)
«We are excited to be a part of this important new initiative to develop novel treatment options for patients,» said Ovid Trifan, M.D., Ph.D., chief medical officer of Apexigen, Inc. «APX005M is a potential best - in - class CD40 agonist that works by activating the immune system's antigen - presenting cells in the tumor microenvironment. (cancerresearch.org)
«Our approach is likely to «revive» genome - wide association studies as a strategy to identify genetic risk factors and to develop novel treatment options for a wide range of diseases, just as people had hoped for when the genetic code was deciphered a decade ago.» (sciencedaily.com)